McLaren Cancer Institute - Flint
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Devisetty, Kiran
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
Bhatt, Amit
ROP3, NCT04634604: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Terminated
3
16
Canada, US
Bevacizumab, Avastin, Laser
Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Retinopathy of Prematurity
08/23
08/23
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
ROP4, NCT04634578: Bevacizumab Treatment For Type 1 ROP

Recruiting
2
80
Canada, US
Bevacizumab, Avastin
Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Retinopathy of Prematurity
07/25
07/27
NCT02236351: New Pediatric Patching Method to Improve Compliance

Recruiting
N/A
200
US
Pinch Patch/ flat Patch
Baylor College of Medicine
Amblyopia, Strabismus
02/24
05/24
NCT05628363: Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Recruiting
N/A
25
US
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, SBRT, Androgen deprivation therapy, ADT
Washington University School of Medicine, Varian Medical Systems
Prostate Cancer, Cancer of the Prostate
04/26
01/31
NCT05581173: Self-Assembling Matrix Forming Gel to Prevent Stricture Formation

Active, not recruiting
N/A
41
US
Purastat SAP gel application
AdventHealth
Esophageal Stricture, Stricture
12/24
12/24
Erickson, Delaney
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
Chalasas, Supraja
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29

Download Options